Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114924 | 0.87 | NTRK1 (0.32) | ACACB | |
| SCHEMBL3821880 | 0.85 | CYP2C9 (0.42) | — | |
| SCHEMBL1884897 | 0.85 | BRD4 (0.33) | TAS2R14 | |
| SCHEMBL14194690 | 0.81 | — | — | |
| SCHEMBL12096416 | 0.78 | CYP2C9 (0.32) | — | |
| SCHEMBL14608968 | 0.78 | CETP (0.32) | — | |
| SCHEMBL858112 | 0.77 | LMNA (0.39) | — | |
| SCHEMBL4280311 | 0.76 | S1PR3 (0.36) | — | |
| SCHEMBL641895 | 0.73 | TAS2R14 (0.37) | ACACBTAS2R14 | |
| SCHEMBL858686 | 0.72 | BRD4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152083-A1 | 5H-PYRR0L0 [2,3-B] PYRAZINE DERIVATIVES FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKACA, KIT, FLT3 | ACACB 2828/4885TAS2R14 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.